Barclays PLC increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 294.2% during ...

EDP-235 is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Enanta Pharmaceuticals (ENTA) announced Tuesday it would appeal a recent U.S. federal court ruling that favored Pfizer (NYSE:PFE) in a patent dispute over the pharma giant’s COVID-19 pill, Paxlovid.

Enanta Pharmaceuticals Inc (ENTA) stock saw a decline, ending the day at $5.75 which represents a decrease of $-0.10 or -1.71% from the prior close of $5.85. The stock opened at $6 and touched a low ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five ...

Technical analysis for Enanta Pharmaceuticals Inc. ENTA including support levels resistance levels and stop losses for ENTA ...

(RTTNews) - Enanta Pharmaceuticals, Inc. (ENTA), a clinical-stage biotechnology company, Monday announced positive topline results from the Phase 2 study evaluating zelicapavir for the treatment ...

Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on Enanta Pharmaceuticals (ENTA – Research Report). The associated price target remains the same with $21.00. Pick the ...

Enanta Pharmaceuticals (ENTA) shares rallied 7.2% in the last trading session to close at $6.28. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Enanta Pharmaceuticals plans to appeal a court decision that Pfizer's Covid-19 antiviral drug, Paxlovid, doesn't infringe on its own patents. The U.S. District Court of Massachusetts ruled that Pfizer ...